Singapore, Aug. 7 -- India-based Intas Pharmaceuticals, in collaboration with its global subsidiaries operating under the Accord brand, has solidified its position as one of the world's leading suppliers of pegfilgrastim following the successful acquisition of UDENYCA(R) (pegfilgrastim-cbqv) from Coherus BioSciences, Inc.

UDENYCA, a biosimilar to Neulasta(R) (pegfilgrastim), significantly expands Intas and Accord's FDA-approved biosimilar portfolio and accelerates their strategic growth in the global biosimilar market.

Accord is already a pegfilgrastim market leader in Europe-having been the first to commercialise a biosimilar pegfilgrastim and the only company to launch an autoinjector- has maintained its leadership despite intense com...